^
Association details:
| Biomarker: | PALB2 deletion |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer
Excerpt:
This report presents a case of recurrent endometrial carcinoma occurring in a woman with a germline pathogenic PALB2 whole-exon deletion. This uncommon finding in a patient with endometrial carcinoma provided the opportunity to use a management strategy of PARP inhibition with olaparib, resulting in a prolonged response to treatment; however, disease progression eventually occurred.
DOI:
10.6004/jnccn.2021.7067
